Zynex (ZYXI) Competitors

Zynex logo
$0.12 0.00 (0.00%)
As of 11/17/2026

ZYXI vs. HSCS, PAVM, IRIX, GUTS, and FEMY

Should you buy Zynex stock or one of its competitors? Zynex's main competitors and comparable companies include HeartSciences (HSCS), PAVmed (PAVM), IRIDEX (IRIX), Fractyl Health (GUTS), and Femasys (FEMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Zynex compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and Zynex (NASDAQ:ZYXI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 294.09%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Zynex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HeartSciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Zynex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Zynex has higher revenue and earnings than HeartSciences. HeartSciences is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeartSciencesN/AN/A-$9.14M-$3.22N/A
Zynex$108.20M0.04$2.99M-$2.43N/A

HeartSciences has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Zynex's return on equity of -804.30% beat HeartSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
HeartSciencesN/A -816.90% -181.97%
Zynex -68.35%-804.30%-36.67%

HeartSciences has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 4.9% of HeartSciences shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, HeartSciences had 2 more articles in the media than Zynex. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Zynex. HeartSciences' average media sentiment score of 0.00 equaled Zynex'saverage media sentiment score.

Company Overall Sentiment
HeartSciences Neutral
Zynex Neutral

Summary

Zynex beats HeartSciences on 7 of the 13 factors compared between the two stocks.

How does Zynex compare to PAVmed?

Zynex (NASDAQ:ZYXI) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

PAVmed has a consensus target price of $56.00, indicating a potential upside of 4,566.67%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Zynex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zynex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PAVmed
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Zynex has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynex$108.20M0.04$2.99M-$2.43N/A
PAVmed$70K137.14$400K-$9.11N/A

Zynex has a net margin of -68.35% compared to PAVmed's net margin of -12,406.76%. PAVmed's return on equity of -70.00% beat Zynex's return on equity.

Company Net Margins Return on Equity Return on Assets
Zynex-68.35% -804.30% -36.67%
PAVmed -12,406.76%-70.00%-17.75%

Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

29.7% of Zynex shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 49.3% of Zynex shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, PAVmed had 7 more articles in the media than Zynex. MarketBeat recorded 7 mentions for PAVmed and 0 mentions for Zynex. PAVmed's average media sentiment score of 0.45 beat Zynex's score of 0.00 indicating that PAVmed is being referred to more favorably in the news media.

Company Overall Sentiment
Zynex Neutral
PAVmed Neutral

Summary

PAVmed beats Zynex on 8 of the 15 factors compared between the two stocks.

How does Zynex compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Zynex (NASDAQ:ZYXI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, IRIDEX had 10 more articles in the media than Zynex. MarketBeat recorded 10 mentions for IRIDEX and 0 mentions for Zynex. IRIDEX's average media sentiment score of 0.08 beat Zynex's score of 0.00 indicating that IRIDEX is being referred to more favorably in the media.

Company Overall Sentiment
IRIDEX Neutral
Zynex Neutral

20.1% of IRIDEX shares are held by institutional investors. Comparatively, 29.7% of Zynex shares are held by institutional investors. 8.6% of IRIDEX shares are held by insiders. Comparatively, 49.3% of Zynex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IRIDEX has a net margin of -6.85% compared to Zynex's net margin of -68.35%. IRIDEX's return on equity of 0.00% beat Zynex's return on equity.

Company Net Margins Return on Equity Return on Assets
IRIDEX-6.85% N/A -11.85%
Zynex -68.35%-804.30%-36.67%

IRIDEX currently has a consensus target price of $3.00, indicating a potential upside of 543.36%. Given IRIDEX's stronger consensus rating and higher probable upside, equities research analysts plainly believe IRIDEX is more favorable than Zynex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIDEX
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Zynex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Zynex has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$52.67M0.16-$4.44M-$0.19N/A
Zynex$108.20M0.04$2.99M-$2.43N/A

IRIDEX has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Summary

IRIDEX beats Zynex on 10 of the 15 factors compared between the two stocks.

How does Zynex compare to Fractyl Health?

Zynex (NASDAQ:ZYXI) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Fractyl Health has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Zynex's return on equity of -804.30% beat Fractyl Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Zynex-68.35% -804.30% -36.67%
Fractyl Health N/A -2,114.58%-91.50%

29.7% of Zynex shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Comparatively, 8.4% of Fractyl Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fractyl Health has a consensus target price of $50.25, suggesting a potential upside of 5,160.13%. Given Fractyl Health's stronger consensus rating and higher probable upside, analysts plainly believe Fractyl Health is more favorable than Zynex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zynex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Fractyl Health
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Fractyl Health had 8 more articles in the media than Zynex. MarketBeat recorded 8 mentions for Fractyl Health and 0 mentions for Zynex. Fractyl Health's average media sentiment score of 0.08 beat Zynex's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the news media.

Company Overall Sentiment
Zynex Neutral
Fractyl Health Neutral

Zynex has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynex$108.20M0.04$2.99M-$2.43N/A
Fractyl Health$90K140.85-$140.95M-$3.11N/A

Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market.

Summary

Fractyl Health beats Zynex on 8 of the 15 factors compared between the two stocks.

How does Zynex compare to Femasys?

Femasys (NASDAQ:FEMY) and Zynex (NASDAQ:ZYXI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Zynex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Femasys$2.29M4.76-$18.63M-$2.06N/A
Zynex$108.20M0.04$2.99M-$2.43N/A

Femasys has a beta of -2.13, indicating that its share price is 313% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

In the previous week, Femasys had 4 more articles in the media than Zynex. MarketBeat recorded 4 mentions for Femasys and 0 mentions for Zynex. Femasys' average media sentiment score of 1.25 beat Zynex's score of 0.00 indicating that Femasys is being referred to more favorably in the media.

Company Overall Sentiment
Femasys Positive
Zynex Neutral

65.3% of Femasys shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Femasys currently has a consensus target price of $50.00, indicating a potential upside of 3,868.25%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts clearly believe Femasys is more favorable than Zynex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Femasys
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Zynex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Zynex has a net margin of -68.35% compared to Femasys' net margin of -640.76%. Femasys' return on equity of -114.48% beat Zynex's return on equity.

Company Net Margins Return on Equity Return on Assets
Femasys-640.76% -114.48% -59.84%
Zynex -68.35%-804.30%-36.67%

Summary

Femasys beats Zynex on 9 of the 16 factors compared between the two stocks.

Get Zynex News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZYXI vs. The Competition

MetricZynexHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.80M$5.92B$7.57B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E Ratio-0.0538.8133.9628.21
Price / Sales0.045.308.375.48
Price / Cash0.5123.4220.7221.66
Price / Book0.114.154.433.65
Net Income$2.99M$143.14M$3.51B$394.00M
7 Day PerformanceN/A-4.70%-5.52%-5.64%
1 Month PerformanceN/A-6.70%-8.70%-9.48%
1 Year Performance-73.81%-1.04%-1.43%-6.81%

Zynex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZYXI
Zynex
N/A$0.13
flat
N/AN/A$3.80M$108.20MN/A770
HSCS
HeartSciences
1.5375 of 5 stars
$2.39
-11.8%
$8.00
+234.7%
-31.6%$13.47MN/AN/A14
PAVM
PAVmed
1.9496 of 5 stars
$1.56
-4.3%
$56.00
+3,489.7%
-89.7%$13.03M$70KN/A41
IRIX
IRIDEX
2.2195 of 5 stars
$0.70
-0.8%
$3.00
+328.4%
-51.0%$12.40M$52.67MN/A108
GUTS
Fractyl Health
1.9312 of 5 stars
$0.81
-9.6%
$50.25
+6,098.3%
-94.0%$11.90M$90KN/A73

Related Companies and Tools


This page (NASDAQ:ZYXI) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners